A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

The successful development of bortezomib-based therapy for treatment of multiple myeloma has established proteasome inhibition as an effective therapeutic strategy, and both 20S proteasome peptidases and 19S deubiquitinases (DUBs) are becoming attractive targets of cancer therapy. It has been report...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Liu, Ningning, Liu, Chunjiao, Li, Xiaofen, Liao, Siyan, Song, Wenbin, Yang, Changshan, Zhao, Chong, Huang, Hongbiao, Guan, Lixia, Zhang, Peiquan, Liu, Shouting, Hua, Xianliang, Chen, Xin, Zhou, Ping, Lan, Xiaoying, Yi, Songgang, Wang, Shunqing, Wang, Xuejun, Dou, Q. Ping, Liu, Jinbao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4050382/
https://ncbi.nlm.nih.gov/pubmed/24912524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep05240
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller